BDBM455427 (R)-3-(4-(4-(1-((1R,2S)-2-methylcyclopentyl)-H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)-1H-pyrazol-1-yl)propane-1,2-diol and (R)-3-(4-(4-(1-((1S,2R)-2-methylcyclopentyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-6-yl)-1H-pyrazol-1-yl)propane-1,2-diol::US10730880, Example 93::US10730880, Example 94::US11028093, Example 94

SMILES C[C@H]1CCC[C@H]1n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(C[C@@H](O)CO)c1

InChI Key InChIKey=VELXQPPVCPGIEB-UHFFFAOYSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 455427   

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM455427(US10730880, Example 93 | US10730880, Example 94 | ...)
Affinity DataIC50: 5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent